Beta-Glucosidase, Fibroblasts
Beta-glucosidase is a lysosomal hydrolytic enzyme responsible for the degradation of glucocerebroside to ceramide and is encoded by the GBA gene. Mutations in GBA results in the defective synthesis of β-glucosidase leading to excessive accumulation of glucocerebrosides in macrophages throughout the reticuloendothelial system. This condition is known as Gaucher disease, which is the most common type of the lysosomal storage disorders. Macrophages with the characteristic ‘ski track’ or ‘wrinkled tissue paper’ cytoplasm can be seen in the liver, spleen, bone marrow, lungs and central nervous system (CNS). Gaucher disease is an autosomal recessive disorder with the prevalence of approximately 1 in 100,000 among the general population but the incidence is particularly common in Ashkenazi Jews (1 in 900).
Depending upon the age of onset and clinical presentation, 3 clinical subtypes of Gaucher disease have been identified. Type 1 is the most common type characterized by hepatosplenomegaly, anemia, thrombocytopenia, coagulation abnormalities, lung disease but lacks CNS involvement. Both type 2 and type 3 Gaucher disease are neuropathic forms with CNS involvement. Type 2 progresses more rapidly and death usually occurs between 2-4 years due to respiratory failure. Type 3 Gaucher disease progresses much slower and patients may survive up to the 3rd or 4th decade. Since enzyme replacement therapy is available for Gaucher disease, prompt diagnosis can significantly improve the clinical outcome.
The enzyme is reduced and, in most cases, absent in Gaucher disease. Therefore, significantly reduced or absent enzyme activity of beta-glucosidase is diagnostic for the disorder. Beta-glucosidase enzyme activity is typically tested in neonatal screening programs using dried blood spots. Enzymatic activity can also be measured using leukocytes or skin fibroblasts. Enzyme testing is not recommended for carrier screening which should be performed by molecular genetic methods. Identification of the specific mutation may be determined either using a target genetic mutation panel, or sequencing of the entire GBA gene.
- Aid in the diagnosis of Gaucher disease
- Aids in differential diagnosis of lysosomal storage diseases
> 8.7 nmol/hour/mg protein
Cultured fibroblasts.
Stability
- Ambient: 48 hours
- Refrigerated: 4-7 days
- Crit Rev Biochem Mol Biol. 1990;25(6):385-414. [PMID: 2127241]
- Clin Genet. 1981 Jan;19(1):16-22. [PMID: 6780254]
- J Pediatr. 2009;155:S10-8. [PMID: 19765407]
- Handb Clin Neurol. 2013;113:1709-15. [PMID: 23622393]
- Eur J Pediatr. 2004;163:58-66. [PMID: 14677061]
- Acta Paediatr Suppl. 2006;95:103-9. [PMID: 16720474]
- Clarke JTR. Clinical guide to inherited metabolic disease 2nd edition, Cambridge press 2004.